Trial Profile
A Phase II Therapeutic Trial of the Use of Dabrafenib and Trametinib in Patients With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Erdheim-Chester disease
- Focus Adverse reactions; Therapeutic Use
- 12 May 2021 Timeframe of primary endpoint changed from 12 to 24 months.
- 30 Aug 2018 Status changed from suspended to completed.
- 19 Aug 2017 Planned End Date changed from 30 Jun 2019 to 30 Dec 2018.